Navigation Links
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
Date:4/23/2009

LOS ANGELES (April 23, 2009) The Food and Drug Administration (FDA) gave its approval this week for Emmaus Medical, Inc. to begin a Phase 3 clinical trial of an experimental treatment for sickle cell disease. The patented experimental treatment was originally developed by investigators led by Yutaka Niihara, MD, MPH, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and is licensed to Emmaus Medical.

The patented drug treatment involves the oral administration of L-glutamine, which is the most common amino acid in the body. This is one of a very few experimental treatments for sickle cell disease to reach the Phase 3 clinical trial stage.

"News of this clinical trial should be of great interest to the millions of people around the world who suffer from painful crises caused by sickle cell disease," said Dr. Niihara. "Phase 3 clinical trials are large, randomized studies conducted at multiple sites to determine the safety and efficacy of a potential treatment. Phase 3 clinical trials are usually the last clinical trials conducted before FDA approval is obtained and the treatment can be made widely available to the patient population."

Sickle cell disease is an inherited disorder that causes red blood cells to become oxidized, sticky and sickle shaped instead of smooth, pliable and round. Sickle cell disease leads to anemia, organ damage, chronic and acute pain and a host of other problems.

"In our Phase 2 clinical trial, we observed an excellent safety profile and positive trends in reducing the number of crises and hospitalizations in sickle cell disease patients," said Dr. Niihara. "We look forward to initiating the Phase 3 clinical trial and remain committed to developing a treatment for sickle cell disease."


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Page: 1

Related medicine news :

1. Anticlotting drug found to be safe in sickle cell patients
2. New Kind of Stem Cells Reverse Sickle Cell Anemia
3. Children with sickle cell disease, silent strokes show some relief with blood transfusions
4. Sickle Cell Disease Pain Can Occur Daily and Is Much More Severe Than Previously Thought
5. Sickle Cell Patients in More Pain Than Thought
6. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
7. For children with sickle cell disease, lung disease is part of the package
8. Lung Trouble Associated With Sickle Cell in Kids
9. Researchers Develop Stem Line With Sickle Cell Mutation
10. Effective treatment for sickle cell underused by doctors
11. Sickle Cell Drug Underused by Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
(Date:1/23/2017)... , ... January 23, 2017 , ... ... and high-level training standards for healthcare treatment providers who treat the full spectrum ... Presidents Council. , The Presidents Council consists of the leading eating disorder ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, ... listeners about the benefits of making new water infrastructure a number one priority. “As ... that we expect water infrastructure to become a top priority of our new political ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... to isolate and purify the desired product. Chemists now spend more time ...
(Date:1/23/2017)... ... January 23, 2017 , ... "ProRandom is a set of camera tools that allow ... looks in Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... layers of text with video footage. ProRandom works by using a virtual camera to ...
(Date:1/23/2017)... ... 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) has ... for women of all ages. The staff of Gynecology Associates of Gwinnett ... from routine health screenings to diagnosing and treating female concerns including menopause, urinary ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, ... clinical data on the Company,s lead investigational immuno-oncology drug ... co-sponsored by the American Society of Clinical Oncology (ASCO), ... Francisco, CA. "AM0010 induces ... CD8 + T cells in the blood and ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic ... Forecasts, 2013 - 2024" report to their offering. ... The global clinical laboratory ... Introduction of innovative solutions on the grounds of maximum ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
Breaking Medicine Technology: